VH CDR3 peptide vaccine

The **VH CDR3 peptide vaccine** is an experimental therapeutic cancer vaccine designed using the unique sequence of the complementarity-determining region 3 (CDR3) of the immunoglobulin heavy chain variable region (VH) from tumor immunoglobulins. This sequence is highly tumor-specific, especially in B-cell malignancies such as chronic lymphocytic leukemia (CLL) and multiple myeloma. By synthesizing peptides based on the tumor-specific VH CDR3 sequence and administering them as vaccines, the goal is to stimulate tumor-specific immune responses—primarily via T cells—against malignant B cells. Immunogenicity studies and early clinical work have demonstrated the feasibility of inducing tumor-specific immune responses in treated patients, sometimes using adjuvants or conjugates like keyhole limpet hemocyanin (KLH) to boost immunogenicity. The peptide vaccine is tailored to each patient's tumor sequence, representing a personalized immunotherapeutic strategy.

Other names

VH CDR3 peptideImmunoglobulin heavy chain variable region CDR3 peptide vaccine